A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis

Dalekos, Georgios N.; Christodoulou, Dimitrios; Kistis, Kostas G.; Zervou, Eleftheria; Hatzis, J.; Tsianos, Epameinondas V.

doi:10.1097/00042737-199811000-00006

Cited by 57 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apart from the almost invariable occurrence of an erythematous roundish plaque at the injection site (Figure 17), administration of INF in HBV patients has been implicated in the following undesired effects (Table 5): skin necrosis at the injection site [110], angioedemaurticaria syndrome [111], diffuse patchy erythematous rash [112], morbilliform exanthema [113], psoriasis [114,115], vitiligo [115], lichen planus [116], ocular trichomegaly [117].…”

Section: Skin Events Related To Infmentioning

confidence: 99%

The Skin and Viral Liver Disease

Mastrolonardo¹

2013

Practical Management of Chronic Viral Hepatitis

View full text Add to dashboard Cite

Section: Skin Events Related To Infmentioning

confidence: 99%

The Skin and Viral Liver Disease

Mastrolonardo¹

2013

Practical Management of Chronic Viral Hepatitis

View full text Add to dashboard Cite

“…For unknown reasons, the effect of ␣-IFN therapy for HCV infection in patients with LP differs markedly from case to case. ␣-IFN has been reported to have no influence (Pawlotsky et al, 1995a), to ameliorate (Doutre et al, 1992(Doutre et al, , 1996Strumia et al, 1993;Hildebrand et al, 1995;Pedersen, 1998;Nagao et al, 1999), or to trigger or worsen LP lesions, mainly in cases with oral involvement (Agner et al, 1992;d'Agay-Abensour et al, 1992;Cayla et al, 1993;Protzer et al, 1993;Sassigneux et al, 1993;Heintges et al, 1994;Papini et al, 1994;Perreard et al, 1994;Barreca et al, 1995;Fornaciari et al, 1995;Nunez et al, 1995;Areias et al, 1996;Nagao et al, 1996b;Schlesinger et al, 1997;Dalekos et al, 1998;Varela et al, 2000;Guijarro et al, 2001). The adjuvant use of ribavirin with ␣-IFN also seems to increase the risk of adverse cutaneous reactions, often of a lichenoid type (Sookoian et al, 1999;Manjón-Haces et al, 2001), whereas data on any effect on the oral mucosa are still lacking.…”

Section: (B) Molecular Mimicrymentioning

confidence: 99%

OralDiseasesPossiblyAssociated withHepatitisC Virus

Carrozzo

Gandolfo

2003

Critical Reviews in Oral Biology & Medicine

View full text Add to dashboard Cite

Morbidity associated with hepatitis C virus (HCV) infection can involve a variety of extrahepatic conditions, including lichen planus (LP) and sialadenitis, predominantly or exclusively involving the oral region, conditions which have been largely neglected in reviews. The literature suggests that HCV-infected patients may frequently have Sjögren-like sialadenitis with mild clinical symptoms, whereas oral LP may be significantly associated with HCV infections in Southern Europe and Japan but not in Northern Europe. These geographical differences could be related to immunogenetic factors such as the HLA-DR6 allele, significantly expressed in Italian patients with OLP and HCV. Analysis of experimental data suggests that HCV could be involved in the pathogenesis of both these diseases. Moreover, parotid lymphoma may arise in patients with sialadenitis, mainly with type II cryoglobulinemia. Little attention has been paid to oral health needs in HCV-infected patients and the variable effect of interferon-alpha therapy on oral tissues. Further research is needed, because of the potentially great influence of oral diseases possibly linked to HCV on the quality of life of millions of patients.

show abstract

“…The most common localized reaction is the formation of transient erythematous pruritic patch, which is mostly resolved without treatment. 3 Other reported adverse reactions at the injection site include iatrogenic cutaneous necrosis, alopecia, bullous eruption, lupus-like eruptions, and lichen planus. 4 Remote cutaneous reactions that were reported with IFN therapy include vitiligo, pityriasis rosea, trichomegaly, vasculitis, allergic eczema, and erythema annulare centrifigum.…”

Section: Introductionmentioning

confidence: 99%

Cutaneous Granulomas Associated With Interferon Therapy

El‐Khalawany

Mohammad

Aboeldahab

et al. 2016

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Treatment with interferon (IFN) could be associated with variable cutaneous adverse reactions. The aim of this study was to describe the clinicopathological spectrum of cutaneous granulomas associated with IFN therapy and identify the causal relation between IFN therapy and granulomatous reactions. The study included 18 patients (16 males and 2 females) with an average age of 48 years. Clinically, most of the lesions were solitary (83.3%) and located on the face (44.4%) and/or trunk (38.9%). The lesions were commonly presented as nodules (33.3%) or plaques (27.8%) with a common size of 5-10 cm. Granulomatous reactions were localized to the injection site in 4 cases, distributed on other body areas (remote granuloma) in 11 cases, and associated with lung involvement (systemic granuloma) in 3 cases. Histologically, injection site granuloma showed suppurative reaction in 75% and sarcoidal reaction in 25%. Remote granuloma showed tuberculoid reaction in 27.3%, interstitial in 27.3%, and sarcoidal in 45.4%. Systemic granuloma showed sarcoidal reaction in all cases. After withdrawal of IFN, only 3 lesions showed spontaneous complete clearance, whereas most of the lesions (83.3%) showed only partial improvement. Our results suggested that IFN is not a causal agent of all associated cutaneous granulomas but it mostly provokes the appearance of granulomatous reactions in susceptible individuals. Findings that prove this concept include the formation of granuloma in body sites away from the injection site, the heterogeneous pattern of granuloma both clinically and histologically, and incomplete clearance of most of the lesions after withdrawal of IFN.

show abstract

A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis

Cited by 57 publications

References 0 publications

The Skin and Viral Liver Disease

The Skin and Viral Liver Disease

OralDiseasesPossiblyAssociated withHepatitisC Virus

Cutaneous Granulomas Associated With Interferon Therapy

Contact Info

Product

Resources

About